Literature DB >> 1333917

Oxidation markedly reduces bilirubin interference in the Jaffé creatinine assay.

G Rajs1, M Mayer.   

Abstract

Bilirubin causes underestimation of serum creatinine in the Jaffé alkaline picrate assay. We report an approach for preventing bilirubin interference by pretreating serum samples with peroxidase and H2O2. The dissociation of bilirubin from albumin and its subsequent oxidation markedly reduces the bilirubin interference and enables accurate determination of creatinine concentrations by the Jaffé reaction even in hyperbilirubinemic sera. Within-run CVs were 2.6%, 4.0%, and 3.8% at mean creatinine concentrations of 88, 165, and 349 mumol/L, respectively (n = 20). Day-to-day CVs were 4.0%, 6.3%, and 5.8% for mean creatinine concentrations of 87, 168, and 364 mumol/L, respectively (n = 12). Average recovery of creatinine added to serum in the presence of 600 mumol/L bilirubin was 97% (n = 15). This method requires only small serum volumes (70 microL) and is easily applicable to automated analyzers that can be programmed to add three reagents consecutively.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1333917

Source DB:  PubMed          Journal:  Clin Chem        ISSN: 0009-9147            Impact factor:   8.327


  3 in total

1.  Comparison of methods, storage conditions, and time to analysis of serum and urine creatinine measured from microsamples by liquid chromatography mass spectrometery (LC/MS) vs. Jaffe.

Authors:  David J Askenazi; John F Moore; Naomi Fineberg; Rajesh Koralkar; Stephanie Clevenger; Jon Daniel Sharer
Journal:  J Clin Lab Anal       Date:  2014-03-20       Impact factor: 2.352

Review 2.  Evaluation and management of critically ill children with acute kidney injury.

Authors:  David Askenazi
Journal:  Curr Opin Pediatr       Date:  2011-04       Impact factor: 2.856

Review 3.  Acute kidney injury in critically ill newborns: what do we know? What do we need to learn?

Authors:  David J Askenazi; Namasivayam Ambalavanan; Stuart L Goldstein
Journal:  Pediatr Nephrol       Date:  2008-12-10       Impact factor: 3.714

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.